1. Home
  2. Analysis
  3. Keytruda
  4. Pulmonary-sarcoidosis

Keytruda and Pulmonary sarcoidosis - a phase IV clinical study of FDA data

Summary:

Pulmonary sarcoidosis is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Mekinist, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Pulmonary sarcoidosis when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Pulmonary sarcoidosis?

Pulmonary sarcoidosis (growth of tiny collections of inflammatory cells in lungs) is found to be associated with 140 drugs and 213 conditions by eHealthMe. Check the latest studies of Pulmonary sarcoidosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 32 people (0.06%) have Pulmonary sarcoidosis.

Could Keytruda cause Pulmonary sarcoidosis?

Among these 32 people:

How long have people been on Keytruda when they have Pulmonary sarcoidosis? *

  • < 1 month: 8.33 %
  • 1 - 6 months: 16.67 %
  • 6 - 12 months: 33.33 %
  • 1 - 2 years: 8.33 %
  • 2 - 5 years: 33.33 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Pulmonary sarcoidosis when taking Keytruda? *

  • female: 64.52 %
  • male: 35.48 %

What is the age of people who have Pulmonary sarcoidosis when taking Keytruda? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 23.08 %
  • 40-49: 3.85 %
  • 50-59: 11.54 %
  • 60+: 61.54 %

What are other drugs people take besides Keytruda? *

  1. Tafinlar: 4 people, 12.50%
  2. Mekinist: 4 people, 12.50%
  3. Metformin: 3 people, 9.38%
  4. Xgeva: 2 people, 6.25%
  5. Vesicare: 2 people, 6.25%
  6. Carboplatin: 2 people, 6.25%
  7. Diprolene: 2 people, 6.25%
  8. Exforge: 2 people, 6.25%
  9. Humalog: 2 people, 6.25%
  10. Keppra: 2 people, 6.25%

What are other side effects people have besides Pulmonary sarcoidosis? *

  1. Cutaneous Sarcoidosis (a multisystem disease with skin lesion): 5 people, 15.62%
  2. Lichenoid Keratosis (a skin disorder described by rapid growing, reddish to brown, benign (noncancerous) lesion on the skin): 4 people, 12.50%
  3. Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 3 people, 9.38%
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 9.38%
  5. Vitiligo (pigment is lost from areas of the skin): 2 people, 6.25%
  6. Thyroiditis (inflammation of thyroid gland): 2 people, 6.25%
  7. Hypoacusis (loss of hearing): 2 people, 6.25%
  8. Malignant Neoplasm Progression (cancer tumour came back): 2 people, 6.25%
  9. Mucosal Inflammation (infection of mucous membrane): 2 people, 6.25%
  10. Muscle Injury: 2 people, 6.25%

What are the existing conditions these people have? *

  1. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 9 people, 28.12%
  2. Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 4 people, 12.50%
  3. High Blood Pressure: 4 people, 12.50%
  4. Hypersensitivity: 4 people, 12.50%
  5. Malignant Melanoma (skin cancer rises from melancytes): 4 people, 12.50%
  6. Acne (skin problems that cause pimples): 4 people, 12.50%
  7. Non-Small Cell Lung Cancer Stage Iiia: 3 people, 9.38%
  8. High Blood Cholesterol: 3 people, 9.38%
  9. Non-Small Cell Lung Cancer Stage Iv: 3 people, 9.38%
  10. Agitation (state of anxiety or nervous excitement): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Pulmonary sarcoidosis?

- Check whether Pulmonary sarcoidosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Pulmonary sarcoidosis treatments and more:

How severe was Pulmonary sarcoidosis and when was it recovered:

Expand to all the drugs that have ingredients of pembrolizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary sarcoidosis:

Browse all the conditions that are associated with Pulmonary sarcoidosis:

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.